Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.

ABSTRACT: The Coalition for Epidemic Preparedness Innovations' "100-day moonshot" aspires to launch a new vaccine within 100 days of pathogen identification, followed by large-scale vaccine availability within the "second hundred days." Here, we describe work to optimize adenoviral vector manufacturing for rapid response, by minimizing time to clinical trial and first large-scale supply, and maximizing output from the available manufacturing footprint. We describe a rapid virus seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a perfusion-based upstream production process, designed to maximize output while retaining simplicity

SUBMITTER: Joe CCD 

PROVIDER: S-EPMC10932548 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature